{"id":34786,"date":"2025-06-05T18:16:08","date_gmt":"2025-06-05T10:16:08","guid":{"rendered":"https:\/\/flcube.com\/?p=34786"},"modified":"2025-06-05T18:16:09","modified_gmt":"2025-06-05T10:16:09","slug":"akeso-biopharma-wins-nmpa-approval-for-new-cadonilimab-indication","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=34786","title":{"rendered":"Akeso Biopharma Wins NMPA Approval for New Cadonilimab Indication"},"content":{"rendered":"\n

China-based Akeso Biopharma (HKG: 9926<\/a>) announced that it has received another indication approval from the National Medical Products Administration (NMPA) for its bispecific antibody (BsAb) drug candidate cadonilimab (AK104). This approval allows cadonilimab to be used in combination with platinum with or without bevacizumab for first-line persistent, recurrent, or metastatic cervical cancer. This addresses an unmet need for immunotherapy in first-line cervical cancer patients in China and marks the third broad-population indication approved for cadonilimab.<\/p>\n\n\n\n

Drug Mechanism and Approval<\/strong>
Cadonilimab targets both programmed death-1 (PD-1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4). It was first conditionally approved in China in June 2022 for patients with recurrent or metastatic cervical cancer who had previously failed platinum-based chemotherapy.<\/p>\n\n\n\n

Previous Approvals<\/strong>
In September of last year, cadonilimab received marketing clearance for use in combination with chemotherapy for first-line unresectable, locally advanced, recurrent, or metastatic gastric or gastroesophageal junction (GC\/GEJ) adenocarcinoma in China.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

China-based Akeso Biopharma (HKG: 9926) announced that it has received another indication approval from the…<\/p>\n","protected":false},"author":1,"featured_media":34787,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[360,16,850,28,18,15],"class_list":["post-34786","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-akeso-biopharma","tag-cancer","tag-hkg-9926","tag-multi-specific-antibodies","tag-pd-1-l1","tag-product-approvals"],"yoast_head":"\nAkeso Biopharma Wins NMPA Approval for New Cadonilimab Indication - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China-based Akeso Biopharma (HKG: 9926) announced that it has received another indication approval from the National Medical Products Administration (NMPA) for its bispecific antibody (BsAb) drug candidate cadonilimab (AK104). This approval allows cadonilimab to be used in combination with platinum with or without bevacizumab for first-line persistent, recurrent, or metastatic cervical cancer. This addresses an unmet need for immunotherapy in first-line cervical cancer patients in China and marks the third broad-population indication approved for cadonilimab.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=34786\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Akeso Biopharma Wins NMPA Approval for New Cadonilimab Indication\" \/>\n<meta property=\"og:description\" content=\"China-based Akeso Biopharma (HKG: 9926) announced that it has received another indication approval from the National Medical Products Administration (NMPA) for its bispecific antibody (BsAb) drug candidate cadonilimab (AK104). This approval allows cadonilimab to be used in combination with platinum with or without bevacizumab for first-line persistent, recurrent, or metastatic cervical cancer. This addresses an unmet need for immunotherapy in first-line cervical cancer patients in China and marks the third broad-population indication approved for cadonilimab.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=34786\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-06-05T10:16:08+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-06-05T10:16:09+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/0509.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34786#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34786\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Akeso Biopharma Wins NMPA Approval for New Cadonilimab Indication\",\"datePublished\":\"2025-06-05T10:16:08+00:00\",\"dateModified\":\"2025-06-05T10:16:09+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34786\"},\"wordCount\":159,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34786#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/0509.webp\",\"keywords\":[\"Akeso Biopharma\",\"Cancer\",\"HKG: 9926\",\"Multi-specific antibodies\",\"PD-1\\\/L1\",\"Product approvals\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=34786#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34786\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=34786\",\"name\":\"Akeso Biopharma Wins NMPA Approval for New Cadonilimab Indication - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34786#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34786#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/0509.webp\",\"datePublished\":\"2025-06-05T10:16:08+00:00\",\"dateModified\":\"2025-06-05T10:16:09+00:00\",\"description\":\"China-based Akeso Biopharma (HKG: 9926) announced that it has received another indication approval from the National Medical Products Administration (NMPA) for its bispecific antibody (BsAb) drug candidate cadonilimab (AK104). This approval allows cadonilimab to be used in combination with platinum with or without bevacizumab for first-line persistent, recurrent, or metastatic cervical cancer. This addresses an unmet need for immunotherapy in first-line cervical cancer patients in China and marks the third broad-population indication approved for cadonilimab.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34786#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=34786\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34786#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/0509.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/0509.webp\",\"width\":1080,\"height\":608,\"caption\":\"Akeso Biopharma Wins NMPA Approval for New Cadonilimab Indication\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34786#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Akeso Biopharma Wins NMPA Approval for New Cadonilimab Indication\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Akeso Biopharma Wins NMPA Approval for New Cadonilimab Indication - Insight, China's Pharmaceutical Industry","description":"China-based Akeso Biopharma (HKG: 9926) announced that it has received another indication approval from the National Medical Products Administration (NMPA) for its bispecific antibody (BsAb) drug candidate cadonilimab (AK104). This approval allows cadonilimab to be used in combination with platinum with or without bevacizumab for first-line persistent, recurrent, or metastatic cervical cancer. This addresses an unmet need for immunotherapy in first-line cervical cancer patients in China and marks the third broad-population indication approved for cadonilimab.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=34786","og_locale":"en_US","og_type":"article","og_title":"Akeso Biopharma Wins NMPA Approval for New Cadonilimab Indication","og_description":"China-based Akeso Biopharma (HKG: 9926) announced that it has received another indication approval from the National Medical Products Administration (NMPA) for its bispecific antibody (BsAb) drug candidate cadonilimab (AK104). This approval allows cadonilimab to be used in combination with platinum with or without bevacizumab for first-line persistent, recurrent, or metastatic cervical cancer. This addresses an unmet need for immunotherapy in first-line cervical cancer patients in China and marks the third broad-population indication approved for cadonilimab.","og_url":"https:\/\/flcube.com\/?p=34786","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-06-05T10:16:08+00:00","article_modified_time":"2025-06-05T10:16:09+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/0509.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=34786#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=34786"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Akeso Biopharma Wins NMPA Approval for New Cadonilimab Indication","datePublished":"2025-06-05T10:16:08+00:00","dateModified":"2025-06-05T10:16:09+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=34786"},"wordCount":159,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=34786#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/0509.webp","keywords":["Akeso Biopharma","Cancer","HKG: 9926","Multi-specific antibodies","PD-1\/L1","Product approvals"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=34786#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=34786","url":"https:\/\/flcube.com\/?p=34786","name":"Akeso Biopharma Wins NMPA Approval for New Cadonilimab Indication - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=34786#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=34786#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/0509.webp","datePublished":"2025-06-05T10:16:08+00:00","dateModified":"2025-06-05T10:16:09+00:00","description":"China-based Akeso Biopharma (HKG: 9926) announced that it has received another indication approval from the National Medical Products Administration (NMPA) for its bispecific antibody (BsAb) drug candidate cadonilimab (AK104). This approval allows cadonilimab to be used in combination with platinum with or without bevacizumab for first-line persistent, recurrent, or metastatic cervical cancer. This addresses an unmet need for immunotherapy in first-line cervical cancer patients in China and marks the third broad-population indication approved for cadonilimab.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=34786#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=34786"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=34786#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/0509.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/0509.webp","width":1080,"height":608,"caption":"Akeso Biopharma Wins NMPA Approval for New Cadonilimab Indication"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=34786#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Akeso Biopharma Wins NMPA Approval for New Cadonilimab Indication"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/0509.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/34786","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=34786"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/34786\/revisions"}],"predecessor-version":[{"id":34788,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/34786\/revisions\/34788"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/34787"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=34786"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=34786"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=34786"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}